Monetary policy still drives investor sentiment

AstraZeneca announced that its lung cancer drug, datopotamab deruxtecan (Dato-DXd), showed a clinically meaningful improvement in overall survival for certain lung cancer patients in a late-stage trial. However, the results did not reach statistical significance in the overall trial population.&nbsp…
© MarketScreener.com 2024